Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

被引：0
|
作者：
Shizuko Sei
Jodie K Mussio
Quan-en Yang
Kunio Nagashima
Ralph E Parchment
Matthew C Coffey
Robert H Shoemaker
Joseph E Tomaszewski
机构：
[1] SAIC-Frederick,Laboratory of Human Toxicology and Pharmacology
[2] Inc,Electron Microscope Laboratory
[3] NCI-Frederick,Developmental Therapeutics Program
[4] SAIC-Frederick,Division of Cancer Treatment and Diagnostics
[5] Inc,undefined
[6] NCI-Frederick,undefined
[7] Oncolytics Biotech Inc,undefined
[8] National Cancer Institute,undefined
[9] National Cancer Institute,undefined
来源：
Molecular Cancer | / 8卷
关键词：
Paclitaxel; Gemcitabine; NSCLC Cell; Combination Index; NSCLC Cell Line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Effectiveness of immunological agents in non-small cell lung cancer
    Rekulapelli, Akhil
    Flausino, Lucas E.
    Iyer, Gayatri
    Balkrishnan, Rajesh
    CANCER REPORTS, 2023, 6 (01)
  • [42] Angiogenesis and antiangiogenic agents in non-small cell lung cancer
    Galligioni, E
    Ferro, A
    LUNG CANCER, 2001, 34 : S3 - S7
  • [43] Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel
    Gandara, DR
    Lara, PN
    Goldberg, Z
    Lau, DHM
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 26 - 32
  • [44] In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines
    Wang, Min-Cong
    Liang, Xuan
    Liu, Zhi-Yan
    Cui, Jie
    Liu, Ying
    Jing, Li
    Jiang, Li-Li
    Ma, Jie-Qun
    Han, Li-Li
    Guo, Qian-Qian
    Yang, Cheng-Cheng
    Wang, Jing
    Wu, Tao
    Nan, Ke-Jun
    Yao, Yu
    ONCOLOGY REPORTS, 2015, 33 (01) : 239 - 249
  • [45] Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting PPARγ
    Ge, Lu-Na
    Yan, Lei
    Li, Cheng
    Cheng, Kai
    MOLECULAR MEDICINE REPORTS, 2019, 20 (03) : 2805 - 2811
  • [46] Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).
    Nakamura, Y.
    Sano, K.
    Fukuda, M.
    Takatani, H.
    Nagashima, S.
    Kinoshita, A.
    Fukuda, M.
    Soda, H.
    Oka, M.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 81S - 81S
  • [47] Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC)
    Iida, Tetsuya
    Nakamura, Yoichi
    Fukuda, Masaski
    Takatani, Hiroshi
    Nagashima, Seiji
    Kinoshita, Akitoshi
    Fukuda, Minoru
    Soda, Hiroshi
    Oka, Mikio
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S462 - S462
  • [48] Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer
    Subhani, Syed
    Jayaraman, Archana
    Jamil, Kaiser
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 71 : 37 - 45
  • [49] Novel cytotoxic agents for non-small cell lung cancer
    Edelman, Martin J.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) : 752 - 755
  • [50] Investigational Agents in the Management of Non-Small Cell Lung Cancer
    Pennell, Nathan A.
    Mekhail, Tarek
    CURRENT ONCOLOGY REPORTS, 2009, 11 (04) : 275 - 284
12345